Posts Tagged ‘Peter Diamandis’


Sunday, April 15th, 2018

Thanks to Peter Diamandis, we recently learned of a new health meter, Viome.  Offering at-home testing (stool samples) and sequencing to identify microorganisms living in the gut, Viome provides a customized recommendation of foods and supplements to optimize microbial functions.  The microbiome is mostly located in the gut and contains trillions of microbes.  According to Viome CEO, Naveen Jain, a healthy microbiome is “part best friend, part power converter, part engine, and part pharmacy.”  These are ten surprising discoveries about the microbiome that Viome has uncovered:

Healthy Food Is Not Always Healthy  You might have been advised to eat your greens, and that greens and nuts are anti-inflammatory. The data show this isn’t always true. Spinach, bran, rhubarb, beets, nuts and nut butters all contain Oxalate. Oxalate-containing food can be harmful, unless you have the microbes present that can metabolize it into a non-harmful substance.  30% of Viome customers lack the microbes to metabolize oxalates properly. In other words, “healthy foods” like spinach are actually not healthy for these people.

“Antioxidants” Aren’t Always Good For Everyone  Like Oxalates, Polyphenols in foods are usually considered very healthy, but unless you have the appropriate microbes that use specific polyphenols, you may not get the full benefit.  One example is a substance found in these foods called Ellagic Acid.  In 50% of people Ellagic Acid is converted it into urolithin A. Only the urolithin A has anti-inflammatory and antioxidant effects. Without the microbes to do this conversion, you will not benefit from the ellagic acid in foods.  Nuts, walnuts, raspberries, pomegranate, blackberries, pecans and cranberries all contain Ellagic acid. (more…)


Sunday, October 29th, 2017

The Food and Drug Administration recently approved a trial to use adipose-derived stem cells to treat non-healing leg ulcers, a common complication of diabetes, in a study conducted by researchers at Sanford Health.  “This clinical trial can help explore treatments for people with non-healing wounds, including people who have diabetes and others with conditions that affect their quality of life,” according to David Pearce, Ph.D., executive vice president of innovation and research at Sanford Health. According to the World Health Organization, in 2014 more than 422 million people have been living with diabetes globally.  The trials, which began in September, followed a similar study in which stem cells were tested for the treatment of shoulder injuries.

While the study has not yet been completed, the FDA’s support indicates growing interest in this arena.  According to Marissa Brassfield of Abundance 360, “this is a great example of how we can use exponential technology advances to tackle large-scale problems — like the 2 to 5 million people living with chronic wounds in the United States alone — which serves to fund a larger vision, refine the technical details, and explore adjacent applications.”